Cardinal Health (CAH) has shown strong performance with a splendid 174% three-year return resulting in a surging stock market value. Their strategic acquisitions continue to bolster the company's portfolio with the acquisition of Integrated Oncology Network, a physician-led independent community oncology network. Additionally, the company has secured a $1 Billion term loan facility and launched the innovative Kendall SCD SmartFlow™ Compression System. The company has expanded its gastroenterology and diabetes businesses with two deals worth $3.9 billion. It is also worth noting that the company's Q1 earnings and revenues have surpassed estimates, and the company has boosted its fiscal year 2025 outlook. The resilient growth amid market shifts is attributed to successful strategic acquisitions and other internal factors, and the company's stock is currently undervalued. Surpassing market gains, this strong momentum makes Cardinal Health a sound long-term pick for value investors.
Cardinal Health CAH News Analytics from Mon, 22 Apr 2024 07:00:00 GMT to Sat, 14 Dec 2024 15:30:22 GMT -
Rating 7
- Innovation 8
- Information 7
- Rumor -5
